Research programme: insulin growth factor-targeted cancer therapies - Systems Medicine/NCI

Drug Profile

Research programme: insulin growth factor-targeted cancer therapies - Systems Medicine/NCI

Alternative Names: hmAb m610; m610

Latest Information Update: 21 Jul 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); Systems Medicine
  • Class Monoclonal antibodies; Peptides; Small molecules
  • Mechanism of Action Insulin-like growth factor I inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jul 2008 Preclinical development is ongoing
  • 25 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
  • 23 Aug 2007 Systems Medicine establishes CRADA with US NCI for the development of anticancer agents
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top